Evidence map›Paper›PMID 33661300›Full record

ArticleBlood advances2021

MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.

Melanie Demers, Sarah Sturtevant, Kevin R Guertin, Dipti Gupta, Kunal Desai, Benjamin F Vieira, Wenjing Li, Alexandra Hicks, Ayman Ismail, Bronner P Gonçalves and 8 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Melanie DemersDepartment of Rare Blood Disorders, Sanofi, Waltham, MA.
Sarah SturtevantDepartment of Rare Blood Disorders, Sanofi, Waltham, MA.
Kevin R GuertinDepartment of Rare Blood Disorders, Sanofi, Waltham, MA.
Dipti GuptaDepartment of Rare Blood Disorders, Sanofi, Waltham, MA.
Kunal DesaiDepartment of Rare Blood Disorders, Sanofi, Waltham, MA.
Benjamin F VieiraDepartment of Rare Blood Disorders, Sanofi, Waltham, MA.
Wenjing LiDepartment of Rare Blood Disorders, Sanofi, Waltham, MA.
Alexandra HicksDepartment of Rare Blood Disorders, Sanofi, Waltham, MA.
Ayman IsmailDepartment of Rare Blood Disorders, Sanofi, Waltham, MA.
Bronner P GonçalvesDepartment of Systems Biology, Harvard Medical School, Massachusetts General Hospital, Boston, MA.
Giuseppe Di CaprioCenter for Systems Biology and.
Ethan SchonbrunCenter for Systems Biology and.
Scott HansenDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN; and.
Faik N MusayevInstitute for Structural Biology, Drug Discovery and Development and.
Martin K SafoInstitute for Structural Biology, Drug Discovery and Development and.
David K WoodDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN; and.
John M HigginsDepartment of Systems Biology, Harvard Medical School, Massachusetts General Hospital, Boston, MA.
David R LightDepartment of Rare Blood Disorders, Sanofi, Waltham, MA.
Sanofi (United States) · USHarvard University · USUniversity of Minnesota · USVirginia Commonwealth University · USCenter for Systems Biology · USUniversity of Miami · US

Funding

X-ray Crystallographic Data Collection SystemS10OD021756 · OD · VIRGINIA COMMONWEALTH UNIVERSITY · PI SAFO, MARTIN K · 2017 to 2017
$600k
NIH HHS S10 OD021756
6 · The paper itself

Abstract

Sickle cell disease (SCD) is associated with hemolysis, vascular inflammation, and organ damage. Affected patients experience chronic painful vaso-occlusive events requiring hospitalization. Hypoxia-induced polymerization of sickle hemoglobin S (HbS) contributes to sickling of red blood cells (RBCs) and disease pathophysiology. Dilution of HbS with nonsickling hemoglobin or hemoglobin with increased oxygen affinity, such as fetal hemoglobin or HbS bound to aromatic aldehydes, is clinically beneficial in decreasing polymerization. We investigated a novel alternate approach to modify HbS and decrease polymerization by inhibiting methionine aminopeptidase 2 (MetAP2), which cleaves the initiator methionine (iMet) from Val1 of α-globin and βS-globin. Kinetic studies with MetAP2 show that βS-globin is a fivefold better substrate than α-globin. Knockdown of MetAP2 in human umbilical cord blood-derived erythroid progenitor 2 cells shows more extensive modification of α-globin than β-globin, consistent with kinetic data. Treatment of human erythroid cells in vitro or Townes SCD mice in vivo with selective MetAP2 inhibitors extensively modifies both globins with N-terminal iMet and acetylated iMet. HbS modification by MetAP2 inhibition increases oxygen affinity, as measured by decreased oxygen tension at which hemoglobin is 50% saturated. Acetyl-iMet modification on βS-globin delays HbS polymerization under hypoxia. MetAP2 inhibitor-treated Townes mice reach 50% total HbS modification, significantly increasing the affinity of RBCs for oxygen, increasing whole blood single-cell RBC oxygen saturation, and decreasing fractional flow velocity losses in blood rheology under decreased oxygen pressures. Crystal structures of modified HbS variants show stabilization of the nonpolymerizing high O2-affinity R2 state, explaining modified HbS antisickling activity. Further study of MetAP2 inhibition as a potential therapeutic target for SCD is warranted.

Indexed as

Anemia, Sickle CellHemoglobin, SickleAminopeptidasesAnimalsAntisickling AgentsHumansKineticsMetalloendopeptidasesMethionyl AminopeptidasesMicePolymerizationAminopeptidasesAntisickling AgentsHemoglobin, SickleMetalloendopeptidasesMetap2 protein, mousemethionine aminopeptidase 2Methionyl Aminopeptidases

Identifiers

PMID33661300
PMCPMC7948285
OpenAlexW2983170435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.